Introduction
Breast cancer is the most prevalent cancer subtype among women worldwide [1] . Breast cancer survival has improved with advanced treatment modalities such as chemotherapy, radiotherapy, and hormone therapy in the last decades [2] [3] [4] . Cardiovascular complications have become more prevalent and important with prolonged survival in these patients [5, 6] . Radiotherapy may cause a broad spectrum of cardiovascular complications including pericarditis, myocardial dysfunction, heart failure, valvular abnormalities, and rhythm disturbances, largely driven by radiotherapy-induced fibrosis [5, 7, 8] . Radiotherapy-induced cardiovascular complications are associated with reduced quality of life, increased mortality, and risk of sudden cardiac death [9, 10] . Fragmented QRS (fQRS) has been shown to be a marker of myocardial fibrosis in various clinical conditions [11] [12] [13] [14] . To date, no study has evaluated the association of locoregional radiotherapy with the development of fQRS in patients with breast cancer. In this study, we aimed to investigate the association between locoregional radiotherapy and development of fQRS on electrocardiography (ECG).
Patients and Methods

Patients
Breast cancer patients receiving locoregional radiotherapy from January 2011 to January 2013 were prospectively enrolled in this study. Patients who had fQRS on ECG before radiotherapy were excluded from the study. Other exclusion criteria were left ventricular systolic dysfunction (left ventricular ejection fraction < 55%), history of coronary artery disease (angina pectoris, myocardial infarction, or revascularization), valvular heart disease, connective tissue disease, and sarcoidosis. All patients were revaluated for the development of fQRS at 1-year follow-up. Prevalence of fQRS in the general population was studied in an age-matched healthy control group. The study protocol was approved by the Institutional Ethics Committee of KTU Faculty of Medicine.
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Assessment of fQRS fQRS (
Radiotherapy Treatment
Radiotherapy was started after the chemotherapy treatment which was administered for 4, 6, or 8 cycles. All patients had a 3-dimensional conformal treatment plan based on computed tomography (CT). CT-based supine simulation was used to assist with the field design. Patients were treated in the supine position. Respiratory control was not performed during the treatment. The region from the mandible to the base of the lung was scanned with 5-mm slice thickness. Heart, lung, and contralateral breast were outlined as organs at risk. The contouring process was guided by the Radiation Therapy Oncology Group (RTOG) Contouring Atlas. Following chemotherapy, all patients received comprehensive external beam radiotherapy to the chest wall and the regional lymphatics as a component of their treatment. Radiation doses were calculated using a dose-volume histogram. All plans were created using the Eclipse TM V.10 treatment planning system (Varian Medical Systems, Inc., Palo Alto, CA, USA), and a 6-MV photon was used as energy. Patients were treated using 3-dimensional conformal radiotherapy. The dosage was 50 Gy in 25 fractions over 5 weeks. Radiotherapy was given after breast-conserving surgery to the whole breast using unopposed tangential fields with 6-MV photon to a median dose of 50 Gy (range 44-50.4). This was followed by a supplemental tumor bed boost up to a median total dose of 60 Gy. The boost was administered by electrons or photons. In patients with risk factors for local recurrence (lymphovascular invasion or close margins), an electron or photon boost to the tumor bed via an additional dose of 10 Gy was implemented. The electron boost was the first choice to reduce radiation exposure to the heart and lungs. However, in some patients, particularly those who had deep seated tumors, we preferred to use photons in order to obtain a more homogenous dose distribution. Infra-or supraclavicular nodal irradiation was also delivered to patients with risk factors for regional recurrence (lymphovascular invasion, positive axillary lymph nodes, or extranodal extension) for a total dose of 50 Gy. Patients with positive hormone receptors received further hormonal therapy.
Statistical Analysis
Continuous variables were expressed as mean ± standard deviation or median and interquartile range (IQR) where appropriate. Categorical variables were presented as frequencies and percentages. The distributions of the continuous variables across the study groups were tested with the Shapiro-Wilks test. Continuous data were analyzed using Student's t-test or Mann-Whitney U test, and categorical data were compared using chi-square or Fisher's exact test. Receiver operating characteristic (ROC) analysis was conducted to assess the discriminative performance of cardiac radiation dose for the development of fQRS. Multivariate logistic regression analyses were conducted to assess association between cardiac radiation dose and development of fQRS. Adjusted odds ratios (ORs) and corresponding confidence intervals (CIs) were presented. A 2-tailed p value < 0.05 was considered statistically significant. All statistical analyses were performed using IBM SPSS software (IBM SPSS Statistics for Windows, Version 21.0; IBM Corp., Armonk, NY, USA).
Results
A total of 52 breast cancer patients (44 invasive ductal, 3 mucinous, 1 papillary, 1 metaplastic, 3 lobular) were included (median age 49 years, IQR 13). Of these, 24 (46.2%) were cases of left-sided breast cancer. 45 (86%) patients received chemotherapy, and 34 (65%) received hormone therapy prior to radiotherapy. Median total and cardiac radiation dose were 50 Gy (IQR 16) and 2.4 Gy (IQR 4.4), respectively. Median cardiac radiation dose was 5.9 Gy (IQR 2.6) for left breast and 1.3 Gy (IQR 0.8) for right breast.
The breast cancer and healthy control groups had a similar baseline cardiovascular risk profile (table 1) . At 1-year follow-up, 19 of 52 (37.4%) breast cancer patients had developed fQRS on ECG. The majority of patients who developed fQRS (13 of 19 (68.4%)) had left-sided breast cancer. Prevalence of fQRS in breast cancer patients was significantly higher (37.4 vs. 11.9%; p = 0.002) as compared to age-matched healthy controls.
Demographic and clinical characteristics of the breast cancer patients with and without fQRS at 1-year follow-up are shown in table 2. Patients who had developed fQRS at 1-year follow-up had more often left-sided breast cancer (68.4 vs. 33.3%; p = 0.015), higher median duration of radiotherapy (30 days, IQR 8 vs. 25 days, IQR 3.8; p = 0.048), and higher median cardiac radiation dose (5 Gy, IQR 5.2 vs. 1.7 Gy IQR 4.4; p = 0.003) as compared to the patients who had not developed fQRS at 1-year follow-up. In addition, the type of chemotherapy and surgery and the number of patients who had received hormone therapy were differed between groups (table 2). Groups were similar with respect to all other baseline characteristics. ROC analysis was conducted to explore the cut-off value of cardiac radiation dose associated with the development of fQRS ( fig. 2) . At a cut-off value of 2.2 Gy, the area under the ROC curve was 0.753 (95% CI 0.621-0.885) with a sensitivity and specificity of 79% (95% CI 54-94) and 64% (95% CI 45-80), respectively. In multivariate logistic regression analysis, total cardiac radiation dose, en- 
Discussion
In this study, we found that 37% of breast cancer patients who received locoregional radiotherapy had developed new fQRS on ECG at 1-year follow-up. Moreover, cardiac radiation dose was independently associated with the development of fQRS.
The risk of cardiovascular complications is increased in breast cancer patients with the advances in adjuvant treatments [16] . As compared to chemotherapy and hormone therapy, cardiovascular complications are more frequent in patients receiving radiotherapy for breast cancer [5, 17] . Fibrosis is considered to be the main pathophysiological mechanism for radiotherapy-induced cardiovascular damage [7, [18] [19] [20] . Thus, early identification of patients with radiotherapy-induced fibrosis may help to prevent progression of the underlying disease and associated clinical conditions.
Myocardial fibrosis can be detected by histopathological evaluation, cardiac magnetic resonance imaging, and scintigraphic meth- ods [21] . However, these imaging modalities and histopathological tests are not readily available, impractical in some cases, and expensive. Myocardial fibrosis may disrupt QRS morphology and lead to fragmentation of QRS on 12-lead ECG. Accordingly, prevalence of fQRS is relatively low among the healthy general population [22] and relatively high in patients with myocardial fibrosis or scarring [11] [12] [13] [14] 23] . These data suggest that fQRS may be a useful tool for the assessment of myocardial fibrosis.
Although ST and T wave changes have been reported after adjuvant treatments [24] , no study to date has evaluated radiotherapyassociated development of fQRS in patients with breast cancer. Our results suggest that more than one-third of breast cancer patients who receive locoregional radiotherapy may develop new fQRS on ECG during 1-year follow-up. Cardiovascular complications have been reported to be associated with cardiac radiation dose [25] . Consistent with this, in the present study, development of fQRS during follow-up was independently associated with cardiac radiation dose.
In conclusion, radiotherapy for breast cancer induces development of new fQRS on ECG. Cardiac radiation dose is independently associated with the development of fQRS. Evaluation of fQRS is an inexpensive and widely available tool and can be used for noninvasive and indirect assessment of myocardial fibrosis in patients receiving radiotherapy.
Limitations
This study has several limitations. The small sample size is the main limitation. Furthermore, duration of post-radiation follow-up was relatively short, and we did not study myocardial fibrosis with advanced imaging modalities. However, recruitment and follow-up are ongoing to power the study and to investigate the long-term cardiac effect of radiotherapy by using ECG, echocardiography, and magnetic resonance imaging. Finally, a possible effect of other treatment modalities including surgery, chemotherapy, and hormone therapy on the development of fQRS could not be totally excluded.
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